Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China
NCT02668640 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 55
Last updated 2019-09-13
Summary
The objective of this study was to assess the effectiveness of adalimumab on health and disability outcomes in participants with rheumatoid arthritis (RA) in China.
Conditions
Interventions
- BIOLOGICAL
-
Pre-filled syringe, administered by subcutaneous injection
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
AbbVie Inc. · AbbVie
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-05-01
- Primary Completion
- 2018-06-12
- Completion
- 2018-08-13
More Related Trials
-
Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis
NCT00650156 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy Study of Adalimumab in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate
NCT00538902 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis
NCT00647491 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Real World Study of a Adalimumab Biosimilar (Geleli) in Rheumatoid Arthritis
NCT05240859 ·Status: UNKNOWN
-
Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.
NCT00195702 ·Status: COMPLETED ·Phase: PHASE3
-
Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis
NCT00235872 ·Status: COMPLETED ·Phase: PHASE3
-
Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis
NCT00650026 ·Status: APPROVED_FOR_MARKETING
-
Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing
NCT00647270 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis
NCT00646386 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects
NCT03357939 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Adalimumab in Japanese Subjects With Rheumatoid Arthritis
NCT00870467 ·Status: COMPLETED ·Phase: PHASE3
-
Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis
NCT06037811 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis
NCT03486457 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis
NCT05414201 ·Status: COMPLETED ·Phase: PHASE4
-
Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing Rapid Progression of Structural Damage of the Joints, Who Have no Prior History of Treatment With Disease-modifying Anti-rheumatic Drugs or Biological Agents
NCT01783730 ·Status: COMPLETED
-
Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy
NCT00646178 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Adalimumab in Patients With Axial Spondyloarthritis
NCT00939003 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Effect of Tocilizumab on Signs and Symptoms in Patients With Rheumatoid Arthritis
NCT00848120 ·Status: COMPLETED ·Phase: PHASE3
-
Prospective Cohort Study on Refractory Rheumatoid Arthritis
NCT07126431 ·Status: RECRUITING
-
Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis
NCT06833112 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia
NCT01387789 ·Status: COMPLETED
-
Adalimumab Administered in Korean Rheumatoid Arthritis Subjects Treated With Methotrexate
NCT00235859 ·Status: COMPLETED ·Phase: PHASE3
-
Multicenter, Post-marketing, Non-interventional, Observational Study in RA Patients Treated With RoActemra/Actemra (Tocilizumab)
NCT02101307 ·Status: COMPLETED
-
Efficacy and Safety of Adalimumab 80 mg Every Other Week With Methotrexate
NCT01270035 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)
NCT02955212 ·Status: COMPLETED ·Phase: PHASE3